Most Read Articles
6 months ago

Associate Professor Ng Lee Ching, Director of the Environmental Health Institute (EHI) at the National Environment Agency (NEA), Singapore, speaks about the role of primary care physicians and government agencies in preventing dengue epidemics.

2 months ago
New drug applications approved by US FDA as of 1 - 15 April 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Christina Lau, 27 days ago

The US FDA recently granted accelerated approval to pembrolizumab for the treatment of adult and paediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumours.

Pearl Toh, 3 days ago
Autoantigen specific therapy with alum-GAD, an investigational “vaccine” against type 1 diabetes (T1D), did not delay or prevent development of the disease in children aged 4–18 years compared with placebo injections in a small study presented at the ADA 2017 Scientific Sessions in San Diego, California, US.

TNF-alpha medication ups risk of tuberculosis

2 months ago

Patients treated with tumour necrosis factor (TNF)-α antagonists may be at a greater risk of tuberculosis (TB), although the biological mechanism underlying this association needs to be elucidated, according to a meta-analysis.

Researchers searched databases including Medline, Embase and Cochrane library for randomised controlled trials (RCTs) reporting TB risk among patients treated with any of the currently available TNF-α antagonists: etanercept (ETN), adalimumab (ADA), infliximab (IFX), golimumab (GOL) and certolizumab pegol (CZP). Exclusion criteria included studies based on unoriginal data, those without data on TB incidence, those that did not observe TB events and articles not published in English.

A total of 29 RCTs involving 11,879 patients were included (n=14 for IFX; n=9 for ADA; n=2 for GOL; n=1 for ETN; n=3 for CZP). A random-effect model was used to calculate odds ratios (ORs) with 95 percent CIs, and subgroup analyses were performed based on type of medication, disease under treatment and TB endemicity. Quality of evidence was evaluated using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach.

Pooled data revealed that TB developed in 45 of 7,912 patients in the TNF-α arms and in three of 3,967 patients in the control arms, yielding an OR of 1.94 (1.10 to 3.44; p=0.02). Results from the subgroup analyses indicated that the effect of TNF-α treatment on TB risk was greater among patients treated for rheumatoid arthritis (OR, 2.29; 1.09 to 4.78; p=0.03). The quality of evidence was low as per the GRADE system.

The present data highlight the importance of considering the potential increase in the risk of TB in the clinical decision concerning treatment with anti-TNF-α drugs; patients should be screened for LTBI and anti-TB prophylaxis before making any decision.

TNF-α antagonists are widely used in in the treatment of rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis and other immune-mediated or inflammation-related diseases. These agents potentially impact on the protective mechanism against infections, especially TB, by increasing the phagocytic capacity of macrophages and enhancing intracellular killing of mycobacterium via the generation of reactive nitrogen and oxygen intermediates. [J Pathol 2008;214:149–60; Ann Rheum Dis 2015;74:1212–17]

“TNF-α is also involved in the pathological changes of latent tuberculous infection, especially in maintaining the formation and function of granuloma which prevents mycobacterium from disseminating into the blood. These TNF-mediated immune mechanisms may explain the reason for the increased risk of TB in patients receiving anti-TNF agents’ treatment,” researchers said.

“Further high-quality research regarding the long-term safety of biologics is needed to improve the safety of biological treatment in clinical use,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
6 months ago

Associate Professor Ng Lee Ching, Director of the Environmental Health Institute (EHI) at the National Environment Agency (NEA), Singapore, speaks about the role of primary care physicians and government agencies in preventing dengue epidemics.

2 months ago
New drug applications approved by US FDA as of 1 - 15 April 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Christina Lau, 27 days ago

The US FDA recently granted accelerated approval to pembrolizumab for the treatment of adult and paediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumours.

Pearl Toh, 3 days ago
Autoantigen specific therapy with alum-GAD, an investigational “vaccine” against type 1 diabetes (T1D), did not delay or prevent development of the disease in children aged 4–18 years compared with placebo injections in a small study presented at the ADA 2017 Scientific Sessions in San Diego, California, US.